Mercer Global Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Mercer Global Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.5K	Sell	21,349 -3,671	-15%	-$14.2K	﹤0.01%	3094
2025 Q4	$100K	Buy	25,020 +8,935	+56%	+$44.3K	﹤0.01%	2716
2025 Q3	$78.5K	Sell	16,085 -12,755	-44%	-$67K	﹤0.01%	2556
2025 Q2	$146K	Sell	28,840 -3,640	-11%	-$17.9K	﹤0.01%	2120
2025 Q1	$172K	Buy	32,480 +6,856	+27%	+$50K	﹤0.01%	2000
2024 Q4	$173K	Sell	25,624 -3,310	-11%	-$22.3K	﹤0.01%	1989
2024 Q3	$179K	Buy	+28,934	New	+$207K	﹤0.01%	1825
2023 Q4	–	Sell	-14,259	Closed	-$109K	–	2079
2023 Q3	$109K	Buy	+14,259	New	+$142K	﹤0.01%	1838

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mercer Global Advisors's RXRX Position: Q1 2026 in Review

Mercer Global Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, selling an estimated $14.2K and leaving 21,349 shares worth $65.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3094.

Mercer Global Advisors first reported a position in RXRX in Q3 2023 and has held it in 8 quarters since. The position peaked at $179K in Q3 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Mercer Global Advisors held 21,349 shares of Recursion Pharmaceuticals worth $65.5K as of Q1 2026.
Mercer Global Advisors sold 3,671 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14.2K.
Recursion Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3094 holding.
Mercer Global Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Mercer Global Advisors's Recursion Pharmaceuticals position peaked at $179K in Q3 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.